Published in J Clin Oncol on March 29, 2010
Disease characteristics, patterns of care, and survival in very elderly patients with diffuse large B-cell lymphoma. Cancer (2015) 2.96
Carboplatin and paclitaxel with vs without bevacizumab in older patients with advanced non-small cell lung cancer. JAMA (2012) 2.56
First-line erlotinib in patients with advanced non-small-cell lung cancer unsuitable for chemotherapy (TOPICAL): a double-blind, placebo-controlled, phase 3 trial. Lancet Oncol (2012) 2.33
Therapeutic potential of anamorelin, a novel, oral ghrelin mimetic, in patients with cancer-related cachexia: a multicenter, randomized, double-blind, crossover, pilot study. Support Care Cancer (2012) 1.87
Lobectomy, sublobar resection, and stereotactic ablative radiotherapy for early-stage non-small cell lung cancers in the elderly. JAMA Surg (2014) 1.86
The impact of comorbidity on cancer survival: a review. Clin Epidemiol (2013) 1.68
Pulmonologist involvement, stage-specific treatment, and survival in adults with non-small cell lung cancer and chronic obstructive pulmonary disease. Ann Am Thorac Soc (2015) 1.40
Impact of age and comorbidity on non-small-cell lung cancer treatment in older veterans. J Clin Oncol (2012) 1.39
Identifying specific chemotherapeutic agents in Medicare data: a validation study. Med Care (2013) 1.36
Socioeconomic inequalities in lung cancer treatment: systematic review and meta-analysis. PLoS Med (2013) 1.31
A novel approach to improve health status measurement in observational claims-based studies of cancer treatment and outcomes. J Geriatr Oncol (2013) 1.16
Addition of rituximab to chemotherapy alone as first-line therapy improves overall survival in elderly patients with mantle cell lymphoma. Blood (2011) 1.12
Intensity modulated radiotherapy for stage III non-small cell lung cancer in the United States: predictors of use and association with toxicities. Lung Cancer (2013) 1.07
Survival among non-small cell lung cancer patients with poor performance status after first line chemotherapy. Lung Cancer (2012) 0.98
Big data analysis of treatment patterns and outcomes among elderly acute myeloid leukemia patients in the United States. Ann Hematol (2015) 0.96
Epidemiology and management of common pulmonary diseases in older persons. J Gerontol A Biol Sci Med Sci (2012) 0.95
Real-world effectiveness of systemic agents approved for advanced non-small cell lung cancer: a SEER-Medicare analysis. Oncologist (2013) 0.91
Patient and physician characteristics associated with erythropoiesis-stimulating agent use in patients with myelodysplastic syndromes. Haematologica (2012) 0.87
Association between the duration of palliative care service and survival in terminal cancer patients. Support Care Cancer (2014) 0.86
Proposal for a novel methodology to screen and score cost versus survival for anticancer drugs in metastatic disease: could cost weigh in evaluation? J Oncol Pract (2012) 0.85
Impact of undetected comorbidity on treatment and outcomes of breast cancer. Int J Breast Cancer (2014) 0.85
Gemcitabine Plus Platinum Combination Chemotherapy for Elderly Patients with Advanced Non-small Cell Lung Cancer: A Retrospective Analysis. Cancer Res Treat (2011) 0.84
Customized chemotherapy based on epidermal growth factor receptor mutation status for elderly patients with advanced non-small-cell lung cancer: a phase II trial. BMC Cancer (2012) 0.83
Chemotherapy Treatment of Elderly Patients (≥70 Years) with Non-Small Cell Lung Cancer: A Seven-Year Retrospective Study of Real-Life Clinical Practice at Karolinska University Hospital, Sweden. Lung Cancer Int (2015) 0.82
Epidemiology and outcomes of previously undiagnosed diabetes in older women with breast cancer: an observational cohort study based on SEER-Medicare. BMC Cancer (2012) 0.81
Cost-effectiveness of stereotactic radiation, sublobar resection, and lobectomy for early non-small cell lung cancers in older adults. J Geriatr Oncol (2015) 0.81
Treatment and outcomes for chronic myelomonocytic leukemia compared to myelodysplastic syndromes in older adults. Haematologica (2012) 0.81
Trends, predictors, and impact of systemic chemotherapy in small cell lung cancer patients between 1985 and 2005. Cancer (2015) 0.81
Current status of chemotherapy use and clinical outcome in octogenarians with advanced non-small cell lung cancer. J Cancer Res Clin Oncol (2014) 0.80
Survival and treatment patterns in elderly patients with advanced non-small-cell lung cancer in Manitoba. Curr Oncol (2011) 0.79
Chemotherapy in Patients Older than or Equal to 75 Years with Advanced Non-small Cell Lung Cancer. Cancer Res Treat (2012) 0.79
Comparison of demographics, treatment patterns, health care utilization, and costs among elderly patients with extensive-stage small cell and metastatic non-small cell lung cancers. BMC Health Serv Res (2014) 0.79
Therapeutic options in older patients with metastatic non-small cell lung cancer. Ther Adv Med Oncol (2012) 0.78
Disparate survival trends in histologic subtypes of metastatic non-small cell lung cancer: a population-based analysis. Am J Cancer Res (2015) 0.78
Customizing systemic therapy in patients with advanced non-small cell lung cancer. Ther Adv Med Oncol (2011) 0.78
Indoleamine 2,3-dioxygenase vaccination. Oncoimmunology (2015) 0.78
Impact on Medical Cost, Cumulative Survival, and Cost-Effectiveness of Adding Rituximab to First-Line Chemotherapy for Follicular Lymphoma in Elderly Patients: An Observational Cohort Study Based on SEER-Medicare. J Cancer Epidemiol (2012) 0.78
Comparative outcomes of oncologic therapy in gastric extranodal marginal zone (MALT) lymphoma: analysis of the SEER-Medicare database. Ann Oncol (2013) 0.77
miRNA-378 reverses chemoresistance to cisplatin in lung adenocarcinoma cells by targeting secreted clusterin. Sci Rep (2016) 0.77
Survival, quality-adjusted survival, and other clinical end points in older advanced non-small-cell lung cancer patients treated with albumin-bound paclitaxel. Br J Cancer (2015) 0.76
Cost-effectiveness of first-line erlotinib in patients with advanced non-small-cell lung cancer unsuitable for chemotherapy. BMJ Open (2015) 0.76
Validation of disability status, a claims-based measure of functional status for cancer treatment and outcomes studies. Med Care (2014) 0.76
Brief versions of the FACIT-fatigue and FAACT subscales for patients with non-small cell lung cancer cachexia. Support Care Cancer (2014) 0.76
Treatment choice in epidermal growth factor receptor mutation-positive non-small cell lung carcinoma: latest evidence and clinical implications. Ther Adv Med Oncol (2017) 0.75
Comparing the mapping between EQ-5D-5L, EQ-5D-3L and the EORTC-QLQ-C30 in non-small cell lung cancer patients. Health Qual Life Outcomes (2016) 0.75
Physician Agency and Patient Survival. J Econ Behav Organ (2016) 0.75
Patterns of Treatment Sequences in Chemotherapy and Targeted Biologics for Metastatic Colorectal Cancer: Findings from a Large Community-Based Cohort of Elderly Patients. Drugs Real World Outcomes (2016) 0.75
Supportive therapy in medical therapy of head and neck tumors. GMS Curr Top Otorhinolaryngol Head Neck Surg (2012) 0.75
Cost-effectiveness of second-line chemotherapy/biologics among elderly metastatic colon cancer patients. Adv Ther (2014) 0.75
Analysis of the characteristics and prognosis of advanced non-small-cell lung cancer in older patients. Patient Prefer Adherence (2015) 0.75
Is there a role of nab-paclitaxel in the treatment of advanced non-small cell lung cancer? The data suggest yes. Eur J Cancer (2016) 0.75
Undertreatment trend in elderly lung cancer patients in Brazil. J Cancer Res Clin Oncol (2017) 0.75
Influence of Age on Guideline-Concordant Cancer Care for Elderly Patients in the United States. Int J Radiat Oncol Biol Phys (2017) 0.75
Obesity may increase the incidence of asthma in women but not in men: longitudinal observations from the Canadian National Population Health Surveys. Am J Epidemiol (2002) 3.01
Randomized phase II trial of erlotinib alone or with carboplatin and paclitaxel in patients who were never or light former smokers with advanced lung adenocarcinoma: CALGB 30406 trial. J Clin Oncol (2012) 2.76
Disease control rate at 8 weeks predicts clinical benefit in advanced non-small-cell lung cancer: results from Southwest Oncology Group randomized trials. J Clin Oncol (2008) 2.64
Gefitinib versus placebo in completely resected non-small-cell lung cancer: results of the NCIC CTG BR19 study. J Clin Oncol (2013) 1.75
Phase I and pharmacokinetic study of sorafenib in patients with hepatic or renal dysfunction: CALGB 60301. J Clin Oncol (2009) 1.75
Lung cancer in women: emerging differences in epidemiology, biology, and therapy. Chest (2005) 1.55
Burden associated with chronic sleep maintenance insomnia characterized by nighttime awakenings among women with menopausal symptoms. Menopause (2010) 1.52
Health disparities in staging of SEER-medicare prostate cancer patients in the United States. Urology (2010) 1.50
Long-term survival in patients with synchronous, solitary brain metastasis from non-small-cell lung cancer treated with radiosurgery. Int J Radiat Oncol Biol Phys (2008) 1.46
Lung cancer patients' CD4(+) T cells are activated in vitro by MHC II cell-based vaccines despite the presence of myeloid-derived suppressor cells. Cancer Immunol Immunother (2008) 1.45
Effect of urologists and medical oncologists on treatment of elderly men with Stage IV prostate cancer. Urology (2011) 1.44
Alpha1-antitrypsin gene therapy modulates cellular immunity and efficiently prevents type 1 diabetes in nonobese diabetic mice. Hum Gene Ther (2006) 1.41
SOX4 cooperates with neurogenin 3 to regulate endocrine pancreas formation in mouse models. Diabetologia (2015) 1.40
Phase II clinical trial of the epothilone B analog, ixabepilone, in patients with non small-cell lung cancer whose tumors have failed first-line platinum-based chemotherapy. J Clin Oncol (2007) 1.32
Phase III trial of methotrexate, vinblastine, doxorubicin, and cisplatin versus carboplatin and paclitaxel in patients with advanced carcinoma of the urothelium. Cancer (2004) 1.31
Phase I study of G3139, a bcl-2 antisense oligonucleotide, combined with carboplatin and etoposide in patients with small-cell lung cancer. J Clin Oncol (2004) 1.26
Promoter methylation and response to chemotherapy and radiation in esophageal cancer. Clin Gastroenterol Hepatol (2006) 1.25
Good research practices for measuring drug costs in cost effectiveness analyses: issues and recommendations: the ISPOR Drug Cost Task Force report--Part I. Value Health (2009) 1.22
The cost of poor sleep: workplace productivity loss and associated costs. J Occup Environ Med (2010) 1.20
A novel approach to improve health status measurement in observational claims-based studies of cancer treatment and outcomes. J Geriatr Oncol (2013) 1.16
Lung cancer in HIV-infected patients in the era of highly active antiretroviral therapy. J Thorac Oncol (2007) 1.15
Phase I and pharmacokinetic study of erlotinib for solid tumors in patients with hepatic or renal dysfunction: CALGB 60101. J Clin Oncol (2007) 1.11
Effect of age on survival benefit of adjuvant chemotherapy in elderly patients with Stage III colon cancer. J Am Geriatr Soc (2009) 1.11
Radiation therapy oncology group protocol 02-29: a phase II trial of neoadjuvant therapy with concurrent chemotherapy and full-dose radiation therapy followed by surgical resection and consolidative therapy for locally advanced non-small cell carcinoma of the lung. Int J Radiat Oncol Biol Phys (2012) 1.06
Preclinical studies of vorinostat (suberoylanilide hydroxamic acid) combined with cytosine arabinoside and etoposide for treatment of acute leukemias. Clin Cancer Res (2009) 1.05
Anti-HDGF targets cancer and cancer stromal stem cells resistant to chemotherapy. Clin Cancer Res (2013) 1.04
High-dose radiotherapy in trimodality treatment of Pancoast tumors results in high pathologic complete response rates and excellent long-term survival. J Thorac Cardiovasc Surg (2005) 1.02
Predictors of acute esophagitis in patients with non-small-cell lung carcinoma treated with concurrent chemotherapy and hyperfractionated radiotherapy followed by surgery. Int J Radiat Oncol Biol Phys (2004) 1.00
Population-based estimates of survival benefit associated with combined modality therapy in elderly patients with locally advanced non-small cell lung cancer. J Thorac Oncol (2011) 0.99
Pemetrexed-induced typhlitis in non-small cell lung cancer. J Thorac Oncol (2008) 0.98
Good research practices for measuring drug costs in cost-effectiveness analyses: Medicare, Medicaid and other US government payers perspectives: the ISPOR Drug Cost Task Force report--Part IV. Value Health (2009) 0.98
Adherence to inhaled corticosteroid use and local adverse events in persistent asthma. Am J Manag Care (2008) 0.97
Neutralizing antibodies elicited by a novel detoxified pneumolysin derivative, PlyD1, provide protection against both pneumococcal infection and lung injury. Infect Immun (2012) 0.97
Optimal duration of chemotherapy in advanced non-small cell lung cancer. Curr Treat Options Oncol (2007) 0.96
Phase I study of folate conjugate EC145 (Vintafolide) in patients with refractory solid tumors. J Clin Oncol (2012) 0.94
Opportunities and challenges in the era of molecularly targeted agents and radiation therapy. J Natl Cancer Inst (2013) 0.93
Algorithm for identifying chemotherapy/biological regimens for metastatic colon cancer in SEER-Medicare. Med Care (2015) 0.93
Phase I trial of high-dose tamoxifen in combination with cisplatin in patients with lung cancer and other advanced malignancies. Cancer Invest (2003) 0.93
Bronchogenic carcinoma in solid organ transplant recipients. Curr Treat Options Oncol (2006) 0.92
Novel, Broad Spectrum Anti-Cancer Agents Containing the Tricyclic 5:7:5-Fused Diimidazodiazepine Ring System. ACS Med Chem Lett (2010) 0.92
Pulmonary resection after curative intent radiotherapy (>59 Gy) and concurrent chemotherapy in non-small-cell lung cancer. Ann Thorac Surg (2004) 0.91
Cancer stem cells and individualized therapy. Cancer Genomics Proteomics (2007) 0.91
Chemotherapy treatment and survival in older women with estrogen receptor-negative metastatic breast cancer: a population-based analysis. J Am Geriatr Soc (2011) 0.91
Assessing quality of life following neoadjuvant therapy for early stage non-small cell lung cancer (NSCLC): results from a prospective analysis using the Lung Cancer Symptom Scale (LCSS). Support Care Cancer (2008) 0.90
Pemetrexed plus cetuximab in patients with recurrent non-small cell lung cancer (NSCLC): a phase I/II study from the Hoosier Oncology Group. J Thorac Oncol (2009) 0.88
EC145: a novel targeted agent for adenocarcinoma of the lung. Expert Opin Investig Drugs (2012) 0.87
Concordance between administrative claims and registry data for identifying metastasis to the bone: an exploratory analysis in prostate cancer. BMC Med Res Methodol (2014) 0.86
West Nile virus presenting as opsoclonus-myoclonus cerebellar ataxia. Neurology (2005) 0.86
Insomnia-related comorbidities and economic costs among a commercially insured population in the United States. Curr Med Res Opin (2009) 0.85
Development of required postgraduate palliative care training for internal medicine residents and medical oncology fellows. J Cancer Educ (2004) 0.85
Phase II randomized study of dose-dense docetaxel and cisplatin every 2 weeks with pegfilgrastim and darbepoetin alfa with and without the chemoprotector BNP7787 in patients with advanced non-small cell lung cancer (CALGB 30303). J Thorac Oncol (2008) 0.85
Increased expression of S100A6 promotes cell proliferation and migration in human hepatocellular carcinoma. J Mol Med (Berl) (2013) 0.85
A phase I dose escalation trial of MAGE-A3- and HPV16-specific peptide immunomodulatory vaccines in patients with recurrent/metastatic (RM) squamous cell carcinoma of the head and neck (SCCHN). Cancer Immunol Immunother (2014) 0.84
KML001 cytotoxic activity is associated with its binding to telomeric sequences and telomere erosion in prostate cancer cells. Clin Cancer Res (2008) 0.84
Regulation of the murine alpha(2)(I) collagen promoter by retinoic acid and retinoid X receptors. Arch Biochem Biophys (2002) 0.83
Abundant microsatellite diversity and oil content in wild Arachis species. PLoS One (2012) 0.83
Defective proliferative responses in B lymphocytes and thymocytes that lack neurofibromin. Mol Immunol (2002) 0.83
Cell cycle-dependent potentiation of cisplatin by UCN-01 in non-small-cell lung carcinoma. Cancer Chemother Pharmacol (2003) 0.83
Asthma costs and utilization in a managed care organization. J Allergy Clin Immunol (2008) 0.83
Treatment options for brain metastases in patients with non-small-cell lung cancer. Curr Oncol Rep (2003) 0.83
Chemotherapy outcomes by histologic subtypes of non-small-cell lung cancer: analysis of the southwest oncology group database for antimicrotubule-platinum therapy. Clin Lung Cancer (2013) 0.82
Economic implications of rasburicase treatment in adult patients with tumour lysis syndrome. Appl Health Econ Health Policy (2012) 0.82
Bortezomib for patients with advanced-stage bronchioloalveolar carcinoma: a California Cancer Consortium Phase II study (NCI 7003). J Thorac Oncol (2011) 0.81
Obatoclax mesylate, a pan-bcl-2 inhibitor, in combination with docetaxel in a phase 1/2 trial in relapsed non-small-cell lung cancer. J Thorac Oncol (2014) 0.81
A retrospective analysis of outcomes by age in a three-arm phase III trial of gemcitabine in combination with carboplatin or paclitaxel vs. paclitaxel plus carboplatin for advanced non-small cell lung cancer. Crit Rev Oncol Hematol (2010) 0.81
Structure-based drug design and potent anti-cancer activity of tricyclic 5:7:5-fused diimidazo[4,5-d:4',5'-f][1,3]diazepines. Bioorg Med Chem (2012) 0.81
[Mapping of two fertility-restoring gene for WA cytoplasmic male sterility in minghui63 using SSR markers]. Yi Chuan Xue Bao (2002) 0.81
MHC II lung cancer vaccines prime and boost tumor-specific CD4+ T cells that cross-react with multiple histologic subtypes of nonsmall cell lung cancer cells. Int J Cancer (2010) 0.80
Impact of metastatic colorectal cancer stage and number of treatment courses on patient health care costs and utilization. Postgrad Med (2013) 0.80
Comparison of acute toxicities in two primary chemoradiation regimens in the treatment of advanced head and neck squamous cell carcinoma. Ann Surg Oncol (2012) 0.80
Economic comparison of rasburicase and allopurinol for treatment of tumor lysis syndrome in pediatric patients. Am J Health Syst Pharm (2010) 0.80
Comparative and cost effectiveness of treatment modalities for hepatocellular carcinoma in SEER-Medicare. Pharmacoeconomics (2014) 0.80
Treatment costs associated with community-acquired pneumonia by community level of antimicrobial resistance. J Antimicrob Chemother (2008) 0.79
Expression of laminin β1 and integrin α2 in the anterior temporal neocortex tissue of patients with intractable epilepsy. Int J Neurosci (2011) 0.79
The synergistic effect of dimethylamino benzoylphenylurea (NSC #639829) and X-irradiation on human lung carcinoma cell lines. Cancer Chemother Pharmacol (2006) 0.79
Phase I study of tirapazamine plus cisplatin/etoposide and concurrent thoracic radiotherapy in limited-stage small cell lung cancer (S0004): a Southwest Oncology Group study. Clin Cancer Res (2004) 0.79
Multispecialist Care and Mortality in Hepatocellular Carcinoma. Am J Clin Oncol (2015) 0.78
Management of common symptoms of advanced lung cancer. Curr Treat Options Oncol (2005) 0.78
Does the type of first-line regimens influence the receipt of second-line chemotherapy treatment? An analysis of 3211 metastatic colon cancer patients. Cancer Med (2014) 0.78
Management of paraneoplastic syndromes in lung cancer. Curr Treat Options Oncol (2004) 0.78
Passive protection of mice against Streptococcus pneumoniae challenge by naturally occurring and vaccine-induced human anti-PhtD antibodies. Hum Vaccin Immunother (2015) 0.78
A comparison of mortality and costs associated with FOLFOX versus FOLFIRI in stage IV colorectal cancer. J Med Econ (2011) 0.78
Preclinical qualification of a new multi-antigen candidate vaccine for metastatic melanoma. J Immunother (2010) 0.78
Evaluation of infectious titer in a candidate HSV type 2 vaccine by a quantitative molecular approach. BMC Microbiol (2013) 0.78
Cyclooxygenase-2 (COX-2) as a predictive marker for the use of COX-2 inhibitors in advanced non-small-cell lung cancer. J Clin Oncol (2012) 0.77
Regulation of alpha 2(I) collagen expression in stellate cells by retinoic acid and retinoid X receptors through interactions with their cofactors. Arch Biochem Biophys (2004) 0.77
Gemcitabine in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy: a phase II California cancer consortium trial. Clin Lung Cancer (2004) 0.77
Transarterial chemoembolization treatment: association between multiple treatments, cumulative expenditures, and survival. Value Health (2013) 0.77
Treatment options for brain metastases in patients with non-small cell lung cancer. Curr Treat Options Oncol (2003) 0.77
Successful treatment of small cell lung cancer during pregnancy. Lung Cancer (2008) 0.77
Assessing the relationship between compliance with antidepressant therapy and employer costs among employees in the United States. J Occup Environ Med (2010) 0.77
Multidisciplinary service utilization pattern by advanced head and neck cancer patients: a single institution study. Int J Otolaryngol (2012) 0.77
[Prediction of yield and yield components in hybrid rice by using molecular markers]. Yi Chuan Xue Bao (2002) 0.77
The effect of amifostine on submandibular gland histology after radiation. Int J Otolaryngol (2012) 0.77
CDC25A(Q110del): a novel cell division cycle 25A isoform aberrantly expressed in non-small cell lung cancer. PLoS One (2012) 0.77
Phase II study of PKC-alpha antisense oligonucleotide aprinocarsen in combination with gemcitabine and carboplatin in patients with advanced non-small cell lung cancer. Lung Cancer (2006) 0.77